Today, most Chinese biopharmaceutical companies have realized the importance of external services and are looking for those that meet their needs and standards. This issue was discussed in detail with CEOs and senior executives at five Chinese biopharmaceutical companies: 3S Bio, Inc., Shanghai Sunway Biotech, Beijing Four Rings Biopharma, Beijing Tri-Prime Gene, and Shenzhen Interlong Biotech Co.
Most Chinese biopharmaceuticals are relatively small and there are not enough of them to sustain a robust services sector. According to Dusheng Cheng, general manager at Beijing Four Rings Biopharma, "Most Chinese biopharmas are small and product distribution is relatively scattered, because most companies have only a few strong-selling products." Cheng says that additional funding would be required to enable companies to complete the entire pharmaceutical process value chain. More importantly, he believes, "Completing the process value chain [internally] would be a waste of capital, manpower, and material. Some of the time-consuming, investment-demanding processes would become a big burden to companies [if they were brought in-house]." More and more Chinese biopharmaceutical companies are seeking external service providers to help complete the whole process.
Yongqing Cheng, general manager at Beijing Tri-Prime agrees, "Facing harsh competition in the domestic market, Chinese biopharmas certainly wish to invest their limited resources in ways that will allow them to be most competitive. Therefore, they really need external services."
Analytical testing, toxicology, and animal test services are among the services that have a great demand in China today. Four Rings Biopharma's Cheng believes that these services are critical because, "Chinese biopharmas find these assays are more strictly evaluated by the State Food and Drug Administration (SFDA)."
Dr. Jing Lou, CEO of 3S Bio, Inc., notes that his company has already contracted out analytical testing such as carbohydrate structure analysis of glycoproteins from mammalian cell-expressed process. Dr. Lou believes that such external services can help ensure in vivo activity in certain glycoproteins such as erythropoietin (EPO) and thrombopoietin (TPO).
Other services in demand include clinical research services, technology transfer, and cell line construction and development. According to Dusheng Cheng, though, "The companies providing these services are still early stage and large-scale professional service companies are not available." Moreover, quality management, training, and drug distribution services (contract sales) are sparse in China. Services that may be required in the near future, but are not in high demand yet, include contract manufacturing, formulation, and stability studies, which today are needed at relatively few companies.